Intravitreal injection of Pegaptanib(Macugen) for chronic central serous chorioretinopathy
- Conditions
- Chronic central serous chorioretinopathy
- Registration Number
- JPRN-UMIN000003931
- Lead Sponsor
- Department of Ophthalmology, Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Not provided
1)Prior treatment with laser or PDT. 2)Signs of choroidal neovascularization. 3)Intra ocular surgeries within 3 month prior to screening, in the study eye. 4)Previously vitrectomized eyes. 5)Past history of systemic disease such as: Diabetic retinopathy. Mild to severe heart failure (Class III or IV assessed by using the New York Heart Association Functional Classification (NYHA)), unstable angina, acute coronary syndrome, myocardial infarction, or ventricular tachycardia Clinically significant peripheral vascular disease (amputation or symptoms of claudication) Renal failure. Liver failure. Cerebral infarction within the preceding 12 months. 6)Previously received radiation therapy to the affected eye. 7)Severe allergic reactions to sodium fluorescein dye, indocyanine green dye or Pegaptanib. 8)Pregnancy or potential pregnancy. 9)Unwilling or unable to follow or comply with all study related procedures.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of subjects improved in best-corrected distance visual acuity (BCVA) at 24 weeks after initiation of pegaptanib.
- Secondary Outcome Measures
Name Time Method 1)Mean change in best corrected visual acuity (BCVA) from baseline at 24 weeks. 2)Proportion of subjects who lose less than 15 letters of BCVA from baseline at 24 weeks. 3)Anatomical change by OCT and fluorescein angiography.